TIDE adheres to the "leading innovation, sustainable innovation" as an important development strategy, the investment in innovative drug research has been increasing, the independent innovation ability has been enhanced. Among them, the platform technology of the R&D center "Establishment and application of key emulsifying technology System in new Pharmaceutical formulation" won the second prize of national Science and Technology Progress award in 2019, and "Industrialization and clinical Application of innovative streptomycin granules conducive to early diagnosis of gastric cancer" won the second prize of Beijing Science and Technology Progress Award in 2019.
The R&D Center has undertaken dozens of National and Beijing major projects, such as the "11th Five-Year Plan", "12th Five-Year Plan", "13th Five-Year Plan", "National Torch Plan", "National International science and Technology Cooperation Project", "National Industrial Foundation Project", "Beijing Science and Technology Plan Project", "Beijing advanced industry development Project" and so on. Most of the R&D products are the first or exclusive innovative projects and have won the Major New Drug Certificate, National Torch Program Project Certificate, Beijing Independent Innovative Product Certificate, Beijing Achievement Award, Beijing New technology and New Product Certificate, etc. By June 2020, 300 invention patents have been applied, among which more than 100 international PCT patents have been applied in more than 20 countries and regions such as the United States, Europe, Japan and Canada.